{
    "organizations": [],
    "uuid": "7e2fa78e37f1a76dff5f55dd240f6149a63fc6c2",
    "author": "",
    "url": "https://www.reuters.com/article/brief-athenex-meets-enrollment-target-fo/brief-athenex-meets-enrollment-target-for-late-stage-breast-cancer-trial-idUSASB0C5YI",
    "ord_in_thread": 0,
    "title": "BRIEF-Athenex Meets Enrollment Target For Late Stage Breast Cancer Trial",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "February 15, 2018 / 1:18 PM / in 6 minutes BRIEF-Athenex Meets Enrollment Target For Late Stage Breast Cancer Trial Reuters Staff Feb 15 (Reuters) - Athenex Inc: * ATHENEX MEETS ENROLLMENT TARGET FOR ORAXOL PHASE III CLINICAL TRIAL IN METASTATIC BREAST CANCER * ATHENEX INC - EXPECTS SECOND INTERIM ANALYSIS IN Q3 OF 2018 Source text for Eikon: Further company coverage:",
    "published": "2018-02-15T15:16:00.000+02:00",
    "crawled": "2018-02-15T15:43:09.001+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "february",
        "pm",
        "minute",
        "meet",
        "enrollment",
        "target",
        "late",
        "stage",
        "breast",
        "cancer",
        "trial",
        "reuters",
        "staff",
        "feb",
        "reuters",
        "athenex",
        "inc",
        "athenex",
        "meet",
        "enrollment",
        "target",
        "oraxol",
        "phase",
        "iii",
        "clinical",
        "trial",
        "metastatic",
        "breast",
        "cancer",
        "athenex",
        "inc",
        "expects",
        "second",
        "interim",
        "analysis",
        "q3",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}